|
시장보고서
상품코드
2094053
임상 의사결정 지원 시스템(CDSS) 시장 : 구성요소별, 유형별, 기술별, 도입 모델별, 기능별, 적응증별, 지역별 - 세계 예측(-2031년)Clinical Decision Support System (CDSS) Market by Type (Therapeutic, Diagnostic), Function (Medication, Treatment Planning, Risk Prediction), Indication (Primary Care, Onco, Cardio), End User (Hospital, ASC, Specialty) AI CDSS - Global Forecast to 2031 |
||||||
임상 의사결정 지원 시스템(CDSS) 시장 규모는 2026년 58억 달러에서 2031년까지 101억 5,000만 달러로 성장할 것으로 예측되며, 예측 기간 동안 CAGR은 11.8%를 기록할 전망입니다.
CDSS와 전자건강기록(EHR), 의사 컴퓨터 처방 입력(CPOE) 플랫폼, AI를 활용한 의료 워크플로우와의 통합이 진행되고 있는 것이, 의료 기관 전반에 걸친 시장 확대를 크게 가속화하고 있습니다. 투약 오류 감소, 임상 효율 향상, 근거 기반 의료 지원, 그리고 환자 안전 강화에 대한 중요성이 부각되면서, 병원 및 의료 시스템 전반에 걸쳐 첨단 CDSS 플랫폼의 보급이 가속화되고 있습니다.
| 조사 범위 | |
|---|---|
| 조사 대상 기간 | 2026-2031년 |
| 기준 연도 | 2025년 |
| 예측 기간 | 2026-2031년 |
| 산정 단위 | 금액(10억 달러) |
| 부문 | 구성요소별, 유형별, 기술별, 도입 모델별, 기능별, 적응증별, 지역별 |
| 대상 지역 | 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카 |
임상 현장에서 인공지능, 예측 분석, 자연어 처리(NLP) 및 클라우드 연동형 의료 기술의 도입 확대가 시장 성장을 더욱 뒷받침하고 있습니다. 또한, 의료의 디지털화, 상호운용성 및 가치 기반 진료 모델에 대한 정부의 관심이 높아짐에 따라, 상호운용성이 보장되고 실시간으로 작동하는 임상 의사결정 지원 솔루션에 대한 수요가 증가하고 있습니다. 의료 IT의 현대화, 커넥티드 헬스케어 생태계, 그리고 엔터프라이즈 임상 인텔리전스 플랫폼에 대한 투자 확대는 예측 기간 동안 전 세계 CDSS 시장의 성장을 더욱 촉진할 것으로 예상됩니다.
"최종사용자별로는, 예측 기간 동안 병원 및 의료 시스템이 가장 높은 성장률을 보일 것으로 예상됩니다."
최종사용자별로 보면 CDSS 시장은 병원 및 통합 의료 시스템, 의사·전문 진료소, 외래 진료 센터, 기타 최종사용자로 구분됩니다. 예측 기간 동안 병원 및 통합 의료 시스템은 엔터프라이즈 의료 기술의 도입 확대와 모든 의료 현장에서 의사결정 지원 시스템에 대한 의존도가 높아지는 것을 배경으로, 가장 규모가 크고 가장 빠르게 성장하는 최종사용자 부문이 될 것으로 전망됩니다. 의료기관은 치료의 정확도 향상, 임상적 편차의 감소, 그리고 환자 안전성 향상을 도모하기 위해 임상의의 업무 흐름, 약물 관리 시스템, 진단 과정, 환자 모니터링 체계에 CDSS 플랫폼을 적극적으로 도입하고 있습니다. 입원 환자 수의 증가, 복잡한 질환의 유병률 상승, 그리고 업무 효율성 향상에 대한 압박이 커짐에 따라, 병원 네트워크 전반에 걸쳐 지능형 의사결정 지원 기술의 대규모 도입이 더욱 가속화되고 있습니다. 상호 운용이 가능한 전자건강기록(EHR), 클라우드 기반 의료 인프라, AI를 활용한 임상 애플리케이션의 광범위한 도입 역시 전 세계 CDSS 시장에서 병원 및 의료 시스템의 주도적 입지를 더욱 공고히 하고 있습니다. 또한, 의료 제공자들은 근거 기반 의료 서비스 제공과 조직 전체의 의료 최적화를 지원하기 위해 예측형 임상 인텔리전스, 워크플로우 자동화, 실시간 진료 조정 기능에 대한 투자를 확대하고 있습니다.
"도입 모델별로는 클라우드형 CDSS 부문이 예측 기간 동안 가장 높은 성장률을 보일 것으로 전망됩니다."
도입 모델에 따라 CDSS 시장은 클라우드형과 온프레미스형으로 분류됩니다. 클라우드 기반 CDSS는 예측 기간 동안 가장 빠른 성장세를 보일 것으로 전망됩니다. 확장성, 상호운용성 및 접근성이 뛰어난 의료 기술의 도입 확대가 모든 의료 환경에서 이러한 수요를 주도하고 있습니다. 의료 서비스 제공자들은 실시간 데이터 교환, 조직 전반에 걸친 임상 협업, AI를 활용한 의사결정, 그리고 EHR 및 디지털 헬스 생태계와의 원활한 통합을 지원하기 위해 클라우드 기반 임상 플랫폼으로의 전환을 가속화하고 있습니다. 통합된 데이터 관리, 유연한 인프라, 초기 도입 비용 절감, 그리고 소프트웨어 업데이트 신속화에 대한 수요가 높아짐에 따라 병원, 외래 진료 센터 및 다중 거점 의료 네트워크 전반에 걸쳐 클라우드 기반 CDSS 솔루션의 도입이 더욱 가속화되고 있습니다. 또한, 원격의료, 커넥티드 케어 솔루션, 원격 환자 모니터링 시스템, AI 기반 의료 애플리케이션의 활용이 확대됨에 따라, 지속적이고 데이터 기반의 환자 관리를 가능하게 하는 클라우드 네이티브 의사결정 지원 기술에 대한 수요가 증가하고 있습니다. 의료용 클라우드 인프라에 대한 투자 증가는 예측 기간 동안 이 부문의 강력한 성장을 더욱 뒷받침할 것으로 전망됩니다.
"아시아태평양은 예측 기간 동안 가장 높은 연평균 성장률(CAGR)을 기록할 것으로 추정됩니다."
CDSS 시장은 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 구분됩니다. 아시아태평양의 CDSS 시장은 예측 기간 동안 가장 높은 연평균 성장률(CAGR)을 기록할 것으로 전망됩니다. 디지털 의료 인프라의 급속한 보급, 상호운용성 기준에 기반한 의료 정보 시스템의 도입 확대, 그리고 AI 기술의 도입이 이러한 추세의 주요 촉진요인으로 작용하고 있습니다. 인도, 중국, 일본, 한국, 싱가포르, 인도네시아 등 각국의 의료 기관들은 클라우드 기반 헬스케어 플랫폼, 전자건강기록(EHR) 시스템, AI 기반 임상 솔루션을 활용하여 임상 환경의 현대화를 적극적으로 추진하고 있습니다. 만성 질환의 유병률 상승, 환자 수 증가, 그리고 근거 기반 임상 워크플로우에 대한 수요 증가로 인해, 해당 지역의 병원 및 의료 네트워크 전반에 걸쳐 첨단 의사결정 지원 기술의 도입이 더욱 가속화되고 있습니다. 또한, 각국 정부는 연계된 의료 서비스 제공과 환자의 장기적인 데이터 관리를 지원하기 위해 국가 차원의 디지털 헬스 이니셔티브와 상호운용성 프로그램을 강화하고 있습니다. 2026년 5월, 인도의 '아유슈만 바라트 디지털 미션(ABDM)'은 100크롤 이상의 의료 기록이 ABHA 계정에 연동되었다고 보고했습니다. 이는 상호운용 가능한 의료 인프라의 개발 및 디지털 환자 기록의 통합 분야에서 상당한 진전이 있었음을 보여줍니다. 의료 IT의 현대화, 확장성이 뛰어난 임상 인텔리전스 플랫폼, 그리고 AI를 활용한 의료 생태계에 대한 투자 확대는 예측 기간 동안 아시아태평양 전체에서 CDSS 시장의 강력한 성장을 지속적으로 견인할 것으로 예상됩니다.
Wolters Kluwer(네덜란드), Epic Systems(미국), Oracle Health(미국), Optum(미국), Merative(미국), Veradigm LLC(미국), Athenahealth, Inc.(미국)는 CDSS 시장의 주요 기업입니다.
본 조사에서는 CDSS 시장의 주요 기업들에 대해 기업 개요, 최근 동향 및 주요 시장 전략을 포함한 상세한 경쟁 분석을 수록하고 있습니다.
조사 범위
본 보고서에서는 CDSS 시장을 분석하고 있습니다. 구성요소, 유형, 기술, 도입 형태, 기능, 적응증, 최종사용자 및 지역별로 각 부문의 시장 규모 및 추정치를 산출하고, 향후 성장 가능성을 예측하고 있습니다. 또한, 본 보고서에서는 주요 기업의 기업 개요, 제품 라인업, 최근 동향 및 주요 시장 전략을 포함한, 이 시장의 주요 참여 기업에 대한 경쟁 분석도 제공하고 있습니다.
이 보고서를 구매해야 하는 이유
본 보고서는 시장을 선도하는 기업 및 신규 진입 기업을 대상으로, CDSS 시장 및 그 하위 부문의 매출액에 대한 가장 정확한 추정치를 제공합니다. 이를 통해 이해관계자들은 경쟁 구도를 파악하고, 자사의 비즈니스를 보다 효과적으로 포지셔닝하며, 적절한 시장 진입 전략을 수립하기 위한 인사이트를 얻을 수 있습니다. 또한, 본 보고서는 이해관계자들이 시장 동향을 파악하는 데 도움이 되며, 주요 시장 촉진요인, 억제요인, 과제 및 기회에 대한 정보를 제공합니다.
본 보고서에서는 다음 사항에 대한 인사이트를 제공합니다:
- 주요 촉진요인(AI 통합형 및 EHR 통합형 CDSS 도입 확대, 투약 오류 및 임상적 비효율성 증가, 디지털화, 상호운용성, 가치 기반 의료에 대한 정부의 관심 증대) 분석, 제약요인(데이터 보안에 대한 우려, 상호운용성 및 통합의 복잡성), 기회(예측 분석 및 생성형 AI의 확대, 클라우드 기반 상호운용 가능한 의료 생태계의 도입 확대, 신흥 경제국에서의 높은 성장 가능성), 그리고 과제(엔터프라이즈 CDSS 플랫폼의 높은 도입 비용, AI 역량을 갖춘 의료 전문가 부족) 등 CDSS 시장의 성장에 영향을 미치는 요인들에 대해 분석하고 있습니다.
- 제품 개발/혁신 : CDSS 시장의 향후 기술, 연구개발 활동 및 신제품·서비스 출시에 관한 상세한 인사이트
- 시장 개발 : 수익성이 높은 시장에 대한 종합적인 정보. 본 보고서에서는 다양한 지역에 걸친 CDSS 시장을 분석하고 있습니다.
- 시장의 다양화 : CDSS 시장의 신제품·서비스, 미개척 지역, 최근 동향 및 투자에 관한 종합적인 정보
- 경쟁사 분석 : Wolters Kluwer(네덜란드), Epic Systems(미국), Oracle Health(미국), Optum(미국), Merative(미국), Veradigm LLC(미국), Athenahealth, Inc.(미국), Elsevier(네덜란드), Zynx Health(미국), Koninklijke Philips N.V.(네덜란드), Medical Information Technology, Inc.(MEDITECH)(미국) 등, CDSS 시장의 주요 기업들의 시장 점유율, 성장 전략, 서비스 제공 내용에 대한 상세한 평가.
자주 묻는 질문
목차
제1장 소개
제2장 주요 요약
제3장 주요 인사이트
제4장 시장 개요
제5장 업계 동향
제6장 기술, 특허, 디지털 기술, AI의 도입에 의한 전략적 파괴
제7장 규제 상황
제8장 고객 상황과 구매 행동
제9장 임상 의사결정 지원 시스템 시장(구성요소별)
제10장 임상 의사결정 지원 시스템 시장(유형별)
제11장 임상 의사결정 지원 시스템 시장(기술별)
제12장 임상 의사결정 지원 시스템 시장(도입 모델별)
제13장 임상 의사결정 지원 시스템 시장(기능별)
제14장 임상 의사결정 지원 시스템 시장(적응증별)
제15장 임상 의사결정 지원 시스템 시장(최종사용자별)
제16장 임상 의사결정 지원 시스템 시장(지역별)
제17장 경쟁 구도
제18장 기업 개요
제19장 조사 방법
제20장 부록
KSM 26.07.28The clinical decision support systems (CDSS) market is expected to grow from USD 5.80 billion in 2026 to USD 10.15 billion by 2031, reflecting a CAGR of 11.8% over the forecast period. The increasing integration of CDSS with electronic health records (EHRs), computerized physician order entry (CPOE) platforms, and AI-enabled healthcare workflows is significantly accelerating market expansion across healthcare organizations. A growing emphasis on reducing medication errors, improving clinical efficiency, supporting evidence-based care, and enhancing patient safety is driving broader adoption of advanced CDSS platforms across hospitals and healthcare systems.
| Scope of the Report | |
|---|---|
| Years Considered for the Study | 2026-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD billion) |
| Segments | Component, Type, Technology, Deployment, Function, Indication, End User, and Region |
| Regions covered | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
Market growth is further supported by the rising implementation of artificial intelligence, predictive analytics, natural language processing (NLP), and cloud-connected healthcare technologies within clinical environments. In addition, increasing government focus on healthcare digitization, interoperability, and value-based care models is strengthening demand for interoperable and real-time clinical decision-support solutions. Expanding investments in healthcare IT modernization, connected healthcare ecosystems, and enterprise clinical intelligence platforms are expected to further support global CDSS market growth throughout the forecast period.
"By end user, hospitals and health systems are expected to witness the highest growth during the forecast period."
By end user, the CDSS market is segmented into hospitals and integrated health systems, physician and specialty practices, ambulatory care centers, and other end users. Hospitals and integrated health systems represent the largest and fastest-growing end-user segment during the forecast period, driven by the increasing deployment of enterprise healthcare technologies and growing dependence on decision support systems across healthcare settings. Healthcare institutions are actively incorporating CDSS platforms into clinician workflows, medication management systems, diagnostic processes, and patient monitoring frameworks to improve treatment accuracy, reduce clinical variation, and strengthen patient safety outcomes. Rising hospital admission volumes, the increasing prevalence of complex diseases, and mounting pressure to improve operational efficiency are further supporting large-scale adoption of intelligent decision-support technologies across hospital networks. The widespread implementation of interoperable electronic health records (EHRs), cloud-enabled healthcare infrastructure, and AI-assisted clinical applications is also reinforcing the dominance of hospitals and health systems within the global CDSS landscape. In addition, healthcare providers are increasingly investing in predictive clinical intelligence, workflow automation, and real-time care coordination capabilities to support evidence-based care delivery and enterprise-wide healthcare optimization.
By deployment model, the cloud-based CDSS segment is expected to witness the highest growth during the forecast period."
Based on deployment model, the CDSS market is segmented into cloud-based and on-premises CDSS. Cloud-based CDSS are projected to register the fastest growth during the forecast period. Rising adoption of scalable, interoperable, and accessible healthcare technologies is driving this demand across healthcare environments. Healthcare providers are increasingly shifting toward cloud-enabled clinical platforms to support real-time data exchange, enterprise-wide clinical coordination, AI-assisted decision-making, and seamless integration with EHRs and digital health ecosystems. The growing need for centralized data management, flexible infrastructure, lower upfront deployment costs, and faster software updates is further accelerating adoption of cloud-based CDSS solutions across hospitals, ambulatory care centers, and multi-site healthcare networks. In addition, the expanding use of telehealth, connected care solutions, remote patient monitoring systems, and AI-driven healthcare applications is strengthening demand for cloud-native decision-support technologies that enable continuous, data-driven patient care. Rising investments in healthcare cloud infrastructure are expected to further support strong segment growth throughout the forecast period.
"Asia Pacific is estimated to register the highest CAGR during the forecast period."
The CDSS market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific CDSS market is projected to register the highest CAGR during the forecast period. Rapid adoption of digital healthcare infrastructure, increased implementation of health information systems based on interoperability standards, and the adoption of AI technologies are among the main drivers of this trend. Healthcare organizations in countries such as India, China, Japan, South Korea, Singapore, and Indonesia are actively promoting the modernization of clinical environments with cloud-powered health platforms, EHR systems, and AI-supported clinical solutions. Rising prevalence of chronic diseases, growing patient populations, and increasing demand for evidence-based clinical workflows are further accelerating the adoption of advanced decision-support technologies across hospitals and healthcare networks in the region. Governments are also strengthening national digital health initiatives and interoperability programs to support connected healthcare delivery and longitudinal patient data management. In May 2026, India's Ayushman Bharat Digital Mission (ABDM) reported that more than 100 crore health records had been linked to ABHA accounts, reflecting substantial progress in interoperable healthcare infrastructure development and digital patient record integration. Increasing investments in healthcare IT modernization, scalable clinical intelligence platforms, and AI-enabled healthcare ecosystems are expected to continue driving strong CDSS market growth across Asia Pacific throughout the forecast period.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the authentication and brand protection marketplace.
- By Company Type: Tier 1 - 45%, Tier 2 - 35%, and Tier - 20%
- By Designation: C-level Executives - 26%, Directors - 17%, and Others - 57%
- By Region: North America - 40%, Europe - 20%, Asia Pacific - 30%, Latin America - 5%, and Middle East - 4%
Wolters Kluwer (Netherlands), Epic Systems (US), Oracle Health (US), Optum (US), Merative (US), Veradigm LLC (US), and Athenahealth, Inc. (US) are key players in the CDSS market.
The study includes an in-depth competitive analysis of these key players in the CDSS market, with their company profiles, recent developments, and key market strategies.
Research Coverage
The report analyzes the CDSS market. It estimates the market size and future growth potential across segments by component, type, technology, deployment, function, indication, end-user, and region. The report also provides a competitive analysis of key players in this market, including their company profiles, product offerings, recent developments, and key market strategies.
Reasons to buy this report
The report will provide market leaders and new entrants with the closest approximations of revenue figures for the CDSS market and its subsegments. It will help stakeholders understand the competitive landscape and gain insights to position their businesses more effectively and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers (increasing adoption of AI-integrated and EHR-integrated CDSS, rising incidence of medication errors and clinical inefficiencies, growing government focus on digitization, interoperability, and value-based care), restraints (data security concerns, interoperability and integration complexity), opportunities (expansion of predictive analytics and generative Al, increasing adoption of cloud-based and interoperable healthcare ecosystems, high growth potential in emerging economies), and challenges (high implementation costs of enterprise CDSS platforms, shortage of AI-skilled healthcare professionals) influencing the growth of the CDSS market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the CDSS market
- Market Development: Comprehensive information about lucrative markets, the report analyzes the CDSS market across varied regions
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the CDSS market
- Competitive Assessment: In-depth assessment of market share, growth strategies, and service offerings of leading players such as Wolters Kluwer (Netherlands), Epic Systems (US), Oracle Health (US), Optum (US), Merative (US), Veradigm LLC (US), Athenahealth, Inc. (US), Elsevier (Netherlands), Zynx Health (US), Koninklijke Philips N.V. (Netherlands), and Medical Information Technology, Inc. (MEDITECH) (US), among others in the CDSS market.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 MARKET SCOPE
- 1.3.1 MARKETS COVERED
- 1.3.2 INCLUSIONS AND EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 STAKEHOLDERS
- 1.6 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
- 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
- 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
- 2.3 DISRUPTIVE TRENDS SHAPING MARKET
- 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
- 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
- 3.1 CLINICAL DECISION SUPPORT SYSTEM MARKET OVERVIEW
- 3.2 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT AND COUNTRY
- 3.3 CLINICAL DECISION SUPPORT SYSTEMS MARKET: REGIONAL GROWTH OPPORTUNITIES
4 MARKET OVERVIEW
- 4.1 INTRODUCTION
- 4.2 MARKET DYNAMICS
- 4.2.1 DRIVERS
- 4.2.1.1 Growing government focus on digitization, interoperability, and value-based care
- 4.2.1.2 Increasing adoption of AI-integrated and EHR-integrated CDSS
- 4.2.1.3 Rising incidence of medication errors and clinical inefficiencies
- 4.2.2 RESTRAINTS
- 4.2.2.1 Data security concerns
- 4.2.2.2 Interoperability and integration complexity
- 4.2.3 OPPORTUNITIES
- 4.2.3.1 Expansion of predictive analytics and Generative AI
- 4.2.3.2 High growth potential in emerging economies
- 4.2.3.3 Increasing adoption of cloud-based and interoperable healthcare ecosystems
- 4.2.4 CHALLENGES
- 4.2.4.1 High implementation costs of enterprise CDSS platforms
- 4.2.4.2 Shortage of AI-skilled healthcare professionals
- 4.2.1 DRIVERS
- 4.3 UNMET NEEDS AND WHITE SPACES
- 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
- 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
- 5.1 PORTER'S FIVE FORCES ANALYSIS
- 5.1.1 THREAT OF NEW ENTRANTS
- 5.1.2 THREAT OF SUBSTITUTES
- 5.1.3 BARGAINING POWER OF SUPPLIERS
- 5.1.4 BARGAINING POWER OF BUYERS
- 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.2 MACROECONOMIC INDICATORS
- 5.2.1 INTRODUCTION
- 5.2.2 GDP TRENDS AND FORECAST
- 5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
- 5.3 VALUE CHAIN ANALYSIS
- 5.3.1 RESEARCH & PRODUCT DEVELOPMENT
- 5.3.2 DATA & KNOWLEDGE ASSETS
- 5.3.3 SOFTWARE & PLATFORM INFRASTRUCTURE
- 5.3.4 CLOUD SERVICE PROVIDERS
- 5.3.5 MARKETING & SALES
- 5.3.6 POST-SALES SERVICES
- 5.4 ECOSYSTEM ANALYSIS
- 5.5 PRICING ANALYSIS
- 5.5.1 INDICATIVE PRICE FOR CDSS MARKET, BY PRODUCT (2025)
- 5.5.2 INDICATIVE PRICE FOR CDSS MAREKT, BY REGION (2025)
- 5.6 KEY CONFERENCES AND EVENTS
- 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 5.8 INVESTMENTS AND FUNDING
- 5.9 CASE STUDY ANALYSIS
- 5.9.1 IMPROVING PATIENT OUTCOMES
- 5.9.2 IMPROVING CLINICAL DECISION-MAKING
- 5.9.3 ENHANCING MEDICATION SAFETY
- 5.9.4 INCREASING CLINICAL EFFICIENCY
- 5.10 IMPACT OF 2025 US TARIFF-OVERVIEW
- 5.10.1 INTRODUCTION
- 5.10.2 KEY TARIFF RATES
- 5.10.3 PRICE IMPACT ANALYSIS
- 5.10.4 IMPACT ON COUNTRY/REGION
- 5.10.4.1 The US
- 5.10.4.2 Europe
- 5.10.4.3 APAC
- 5.10.5 IMPACT ON END USE INDUSTRIES
6 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL, AND AI ADOPTION
- 6.1 KEY EMERGING TECHNOLOGIES
- 6.1.1 DEEP LEARNING & PREDICTIVE CLINICAL ANALYTICS TECHNOLOGIES
- 6.1.2 NATURAL LANGUAGE PROCESSING (NLP) & GENERATIVE AI TECHNOLOGIES
- 6.1.3 REAL-TIME INTELLIGENCE & WORKFLOW-ORIENTED AI TECHNOLOGIES
- 6.2 COMPLEMENTARY TECHNOLOGIES
- 6.2.1 ELECTRONIC HEALTH RECORDS (EHR), FHIR & HEALTHCARE INTEROPERABILITY TECHNOLOGIES
- 6.2.2 CLOUD-BASED, EDGE & HYBRID CLINICAL COMPUTING TECHNOLOGIES
- 6.3 ADJACENT TECHNOLOGIES
- 6.3.1 AMBIENT CLINICAL OPERATIONAL & DOCUMENTATION TECHNOLOGIES
- 6.3.2 DIAGNOSTIC AND IMAGING TECHNOLOGIES
- 6.4 TECHNOLOGY/PRODUCT ROADMAP
- 6.5 PATENT ANALYSIS
- 6.5.1 PATENT PUBLICATION TRENDS FOR CLINICAL DECISION SUPPORT SYSTEMS
- 6.5.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
- 6.5.3 LIST OF SOME PATENTS/PATENT APPLICATIONS FOR CDSS
- 6.6 FUTURE APPLICATIONS
- 6.6.1 AI-ASSISTED PERSONALIZED CLINICAL DECISION SUPPORT
- 6.6.2 AMBIENT CLINICAL INTELLIGENCE & AUTONOMOUS WORKFLOW ASSISTANCE
- 6.6.3 PREDICTIVE POPULATION HEALTH & CONTINUOUS CARE MANAGEMENT
- 6.7 IMPACT OF AI/GEN AI ON CDSS MARKET
- 6.7.1 INTRODUCTION
- 6.7.2 MARKET POTENTIAL OF AI/GEN AI IN CDSS MARKET
- 6.7.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION
- 6.7.4 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
- 6.7.4.1 Electronic Health Records (EHR) & Healthcare Interoperability
- 6.7.4.2 Remote Patient Monitoring (RPM), Telehealth & Digital Care
- 6.7.4.3 Population Health Management (PHM)
- 6.7.5 USER READINESS AND IMPACT ASSESSMENT
- 6.7.5.1 User Readiness
- 6.7.5.1.1 User A: Hospitals & Integrated Health Systems
- 6.7.5.1.2 User B: Ambulatory Care Centers & Physician Practices
- 6.7.5.2 Impact Assessment
- 6.7.5.2.1 User A: Hospitals & Integrated Health Systems
- 6.7.5.2.1.1 IMPLEMENTATION
- 6.7.5.2.1.2 IMPACT
- 6.7.5.2.2 User B: Ambulatory Care Centers & Physician Practices
- 6.7.5.2.2.1 IMPLEMENTATION
- 6.7.5.2.2.1.1 IMPACT
- 6.7.5.2.2.1 IMPLEMENTATION
- 6.7.5.2.1 User A: Hospitals & Integrated Health Systems
- 6.7.5.1 User Readiness
7 REGULATORY LANDSCAPE
- 7.1 REGIONAL REGULATIONS AND COMPLIANCE
- 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 7.1.2 REGULATORY FRAMEWORK
- 7.1.2.1 North America
- 7.1.2.2 Europe
- 7.1.2.3 Asia Pacific
- 7.1.2.4 Latin America
- 7.1.2.5 Middle East & Africa
- 7.1.3 INDUSTRY STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
- 8.1 INTRODUCTION
- 8.2 DECISION-MAKING PROCESS
- 8.3 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
- 8.4 KEY STAKEHOLDERS IN BUYING PROCESS
- 8.4.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 8.4.2 BUYING CRITERIA
- 8.5 ADOPTION BARRIERS & INTERNAL CHALLENGES
- 8.6 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
- 8.6.1 UNMET NEEDS
- 8.6.2 END-USER EXPECTATIONS
- 8.7 MARKET PROFITABILITY
9 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT
- 9.1 INTRODUCTION
- 9.2 SOFTWARE
- 9.2.1 INTEGRATED CDSS
- 9.2.1.1 EHR integration and real-time clinical decision support to drive market growth
- 9.2.2 STANDALONE CDSS
- 9.2.2.1 Specialized clinical decision support applications to support market growth
- 9.2.1 INTEGRATED CDSS
- 9.3 SERVICES
- 9.3.1 SPECIALIZED APPLICATIONS TO SUPPORT RECURRING REQUIREMENT TO DRIVE MARKET
10 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE
- 10.1 INTRODUCTION
- 10.2 THERAPEUTIC CDSS
- 10.2.1 INCREASING DEMAND FOR EVIDENCE-BASED TREATMENT DECISION SUPPORT TO DRIVE MARKET GROWTH
- 10.3 DIAGNOSTIC CDSS
- 10.3.1 INCREASING DEMAND FOR ACCURATE AND TIMELY DIAGNOSTIC DECISION SUPPORT TO BOOST MARKET
11 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TECHNOLOGY
- 11.1 INTRODUCTION
- 11.2 KNOWLEDGE-BASED CDSS
- 11.2.1 DEPLOYS CONDITIONAL LOGIC FOR DECISION-MAKING AND PROBLEM ANALYSIS
- 11.3 NON-KNOWLEDGE-BASED CDSS
- 11.3.1 ADVANCEMENTS IN AI AND PREDICTIVE ANALYTICS TO DRIVE MARKET EXPANSION
12 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DEPLOYMENT MODEL
- 12.1 INTRODUCTION
- 12.2 CLOUD-BASED
- 12.2.1 SCALABILITY, INTEROPERABILITY, AND AI-ENABLED WORKFLOWS BOOST GROWTH
- 12.3 ON-PREMISES
- 12.3.1 GREATER DATA CONTROL AND CUSTOMIZATION TO SUPPORT CONTINUED ADOPTION
13 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY FUNCTION
- 13.1 INTRODUCTION
- 13.2 MEDICATION MANAGEMENT SUPPORT
- 13.2.1 INCREASING FOCUS ON MEDICATION SAFETY AND ERROR REDUCTION TO DRIVE MARKET GROWTH
- 13.3 DIAGNOSTIC DECISION SUPPORT
- 13.3.1 GROWING DEMAND FOR ACCURATE AND TIMELY DIAGNOSTIC INSIGHTS TO DRIVE MARKET GROWTH
- 13.4 TREATMENT PLANNING & CLINICAL PATHWAY SUPPORT
- 13.4.1 INCREASING ADOPTION OF EVIDENCE-BASED CARE PATHWAYS TO SUPPORT MARKET EXPANSION
- 13.5 RISK PREDICTION & PREVENTIVE CARE
- 13.5.1 EXPANDING USE OF PREDICTIVE ANALYTICS TO DRIVE MARKET GROWTH
- 13.6 OTHER FUNCTIONS
14 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INDICATION
- 14.1 INTRODUCTION
- 14.2 PRIMARY CARE & GENERAL MEDICINE
- 14.2.1 INCREASING DEMAND FOR EVIDENCE-BASED DECISION SUPPORT IN HIGH-VOLUME CARE SETTINGS TO DRIVE MARKET GROWTH
- 14.3 ONCOLOGY
- 14.3.1 INCREASING COMPLEXITY OF CANCER CARE SUPPORTS MARKET EXPANSION
- 14.4 CARDIOLOGY
- 14.4.1 GROWING DEMAND FOR CARDIOVASCULAR RISK STRATIFICATION AND CLINICAL DECISION SUPPORT
- 14.5 CRITICAL CARE & EMERGENCY MEDICINE
- 14.5.1 REAL-TIME CLINICAL DECISION SUPPORT TO IMPROVE ACUTE CARE OUTCOMES
- 14.6 NEUROLOGY
- 14.6.1 ADVANCEMENTS IN AI-ENABLED NEUROLOGICAL DECISION SUPPORT TO DRIVE MARKET GROWTH
- 14.7 OTHERS
- 14.7.1 ABILITY TO ENABLE OPTIMAL DECISION-MAKING WITH MINIMAL ERRORS TO DRIVE MARKET
15 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY END USER
- 15.1 INTRODUCTION
- 15.2 HOSPITALS & HEALTH SYSTEMS
- 15.2.1 INCREASING ADOPTION OF ENTERPRISE-WIDE CLINICAL DECISION SUPPORT TO DRIVE MARKET GROWTH
- 15.3 PHYSICIAN & SPECIALTY PRACTICES
- 15.3.1 GROWING NEED FOR EFFICIENT CLINICAL DECISION-MAKING TO SUPPORT MARKET EXPANSION
- 15.4 AMBULATORY CARE CENTERS
- 15.4.1 EXPANDING OUTPATIENT CARE DELIVERY TO ACCELERATE CDSS ADOPTION
- 15.5 OTHER END USERS
- 15.5.1 EXPANDING UTILIZATION OF CLINICAL DECISION SUPPORT ACROSS DIVERSE HEALTHCARE SETTINGS
16 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY REGION
- 16.1 INTRODUCTION
- 16.2 NORTH AMERICA
- 16.2.1 NORTH AMERICA: MACROECONOMIC IMPACT
- 16.2.2 US
- 16.2.2.1 Expansion of AI-enabled value-based care to accelerate CDSS adoption
- 16.2.3 CANADA
- 16.2.3.1 Accelerating digital health interoperability to strengthen CDSS adoption
- 16.3 EUROPE
- 16.3.1 EUROPE: MACROECONOMIC IMPACT
- 16.3.2 GERMANY
- 16.3.2.1 Favorable government support for digital health and electronic patient records to propel market
- 16.3.3 UK
- 16.3.3.1 NHS digital transformation and interoperable healthcare infrastructure drive market
- 16.3.4 FRANCE
- 16.3.4.1 Robust interoperability for EHR systems to drive market
- 16.3.5 ITALY
- 16.3.5.1 Expansion of interoperable electronic health records to accelerate CDSS adoption
- 16.3.6 SPAIN
- 16.3.6.1 Growing adoption of interoperable electronic health records to support market growth
- 16.3.7 REST OF EUROPE
- 16.4 ASIA PACIFIC
- 16.4.1 ASIA PACIFIC: MACROECONOMIC IMPACT
- 16.4.2 JAPAN
- 16.4.2.1 Medical DX initiatives and standardized electronic medical records to propel market
- 16.4.3 CHINA
- 16.4.3.1 Government-led digital hospital transformation and EMR maturity to drive market
- 16.4.4 INDIA
- 16.4.4.1 Expansion of Ayushman Bharat Digital Mission to accelerate CDSS adoption
- 16.4.5 AUSTRALIA
- 16.4.5.1 Nationwide adoption of My Health Record to accelerate CDSS deployment
- 16.4.6 SOUTH KOREA
- 16.4.6.1 Government-led digital health regulations and AI adoption to drive market
- 16.4.7 REST OF ASIA PACIFIC
- 16.5 LATIN AMERICA
- 16.5.1 LATIN AMERICA: MACROECONOMIC IMPACT
- 16.5.2 BRAZIL
- 16.5.2.1 Strengthening national health information exchange to accelerate CDSS adoption
- 16.5.3 MEXICO
- 16.5.3.1 Digital transformation initiatives in healthcare to support CDSS adoption
- 16.5.4 REST OF LATIN AMERICA
- 16.5.4.1 Growing healthcare digitalization to support CDSS adoption
- 16.6 MIDDLE EAST & AFRICA
- 16.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC IMPACT
- 16.6.2 GCC COUNTRIES
- 16.6.2.1 Rising demand to digitize healthcare IT to propel market
- 16.6.3 SAUDI ARABIA
- 16.6.3.1 National digital health transformation to accelerate CDSS adoption
- 16.6.4 UAE
- 16.6.4.1 Expansion of nationwide health information exchange to drive market
- 16.6.5 OTHER GCC COUNTRIES
- 16.6.5.1 Increasing digital health investments to support CDSS adoption
- 16.6.6 SOUTH AFRICA
- 16.6.6.1 Focus on modernizing healthcare systems to drive market
- 16.6.7 REST OF MIDDLE EAST & AFRICA
- 16.6.7.1 Growing government-led digital health initiatives to support market growth
17 COMPETITIVE LANDSCAPE
- 17.1 OVERVIEW
- 17.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023-2026
- 17.3 REVENUE ANALYSIS, 2021-2025
- 17.4 MARKET SHARE ANALYSIS, 2021-2025
- 17.5 BRAND COMPARISON
- 17.6 COMPANY VALUATION AND FINANCIAL METRICS
- 17.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
- 17.7.1 STARS
- 17.7.2 EMERGING LEADERS
- 17.7.3 PERVASIVE PLAYERS
- 17.7.4 PARTICIPANTS
- 17.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
- 17.7.5.1 Company footprint
- 17.7.5.2 Region footprint
- 17.7.5.3 Component footprint
- 17.7.5.4 Type footprint
- 17.7.5.5 Technology footprint
- 17.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
- 17.8.1 PROGRESSIVE COMPANIES
- 17.8.2 RESPONSIVE COMPANIES
- 17.8.3 DYNAMIC COMPANIES
- 17.8.4 STARTING BLOCKS
- 17.8.4.1 COMPETITIVE BENCHMARKING STARTUPS/SMES, 2025
- 17.9 COMPETITIVE SCENARIO
- 17.9.1 DEALS
- 17.9.2 OTHER DEVELOPMENTS
18 COMPANY PROFILES
- 18.1 KEY PLAYERS
- 18.1.1 WOLTERS KLUWER N.V.
- 18.1.1.1 Business overview
- 18.1.1.2 Product/solutions/services s offered
- 18.1.1.3 Recent developments
- 18.1.1.3.1 Product launches & upgrades
- 18.1.1.3.2 Deals
- 18.1.1.3.3 Other developments
- 18.1.1.4 MnM view
- 18.1.1.4.1 Key strengths
- 18.1.1.4.2 Strategic choices
- 18.1.1.4.3 Weaknesses and competitive threats
- 18.1.2 EPIC SYSTEMS CORPORATION
- 18.1.2.1 Business overview
- 18.1.2.2 Products/solutions/services offered
- 18.1.2.3 Recent developments
- 18.1.2.3.1 Product launches & upgrades
- 18.1.2.3.2 Deals
- 18.1.2.3.3 Other developments
- 18.1.2.4 MnM view
- 18.1.2.4.1 Key strengths
- 18.1.2.4.2 Strategic choices
- 18.1.2.4.3 Weaknesses and competitive threats
- 18.1.3 ORACLE
- 18.1.3.1 Business overview
- 18.1.3.2 Products/solutions/services offered
- 18.1.3.3 Recent developments
- 18.1.3.3.1 Product launches & upgrades
- 18.1.3.3.2 Deals
- 18.1.3.4 MnM view
- 18.1.3.4.1 Key strengths
- 18.1.3.4.2 Strategic choices
- 18.1.3.4.3 Weaknesses and competitive threats
- 18.1.4 MERATIVE
- 18.1.4.1 Business overview
- 18.1.4.2 Products/solutions/services offered
- 18.1.4.3 Recent developments
- 18.1.4.3.1 Product launches & upgrades
- 18.1.4.3.2 Deals
- 18.1.4.3.3 Other developments
- 18.1.4.4 MnM view
- 18.1.4.4.1 Key strengths
- 18.1.4.4.2 Strategic choices
- 18.1.4.4.3 Weaknesses and competitive threats
- 18.1.5 VERADIGM LLC
- 18.1.5.1 Business overview
- 18.1.5.2 Products/solutions/services offered
- 18.1.5.3 Recent developments
- 18.1.5.3.1 Product launches & upgrades
- 18.1.5.3.2 Deals
- 18.1.5.3.3 Other developments
- 18.1.5.4 MnM view
- 18.1.5.4.1 Key strengths
- 18.1.5.4.2 Strategic choices
- 18.1.5.4.3 Weaknesses and competitive threats
- 18.1.6 OPTUM, INC. (UNITEDHEALTH GROUP)
- 18.1.6.1 Business overview
- 18.1.6.2 Products/solutions/services offered
- 18.1.6.3 Recent developments
- 18.1.6.3.1 Product launches & upgrades
- 18.1.6.3.2 Deals
- 18.1.7 ATHENAHEALTH
- 18.1.7.1 Business overview
- 18.1.7.2 Products/solutions/services offered
- 18.1.7.3 Recent developments
- 18.1.7.3.1 Product launches & upgrades
- 18.1.7.3.2 Deals
- 18.1.8 ELSEVIER (DIVISION OF RELX GROUP)
- 18.1.8.1 Business overview
- 18.1.8.2 Products/solutions/services offered
- 18.1.8.3 Recent developments
- 18.1.8.3.1 Product launches & upgrades
- 18.1.8.3.2 Deals
- 18.1.9 ZYNX HEALTH, INC.
- 18.1.9.1 Business overview
- 18.1.9.2 Products/solutions/services offered
- 18.1.9.3 Recent developments
- 18.1.9.3.1 Product launches & upgrades
- 18.1.9.3.2 Deals
- 18.1.9.3.3 Other developments
- 18.1.10 KONINKLIJKE PHILIPS N.V.
- 18.1.10.1 Business overview
- 18.1.10.2 Products/solutions/services offered
- 18.1.10.3 Recent developments
- 18.1.10.3.1 Product launches & upgrades
- 18.1.10.3.2 Deals
- 18.1.11 MEDICAL INFORMATION TECHNOLOGY, INC.
- 18.1.11.1 Business overview
- 18.1.11.2 Products/solutions/services offered
- 18.1.11.3 Recent developments
- 18.1.11.3.1 Product launches & upgrades
- 18.1.11.3.2 Deals
- 18.1.11.3.3 Other developments
- 18.1.12 NEXTGEN HEALTHCARE, INC.
- 18.1.12.1 Business overview
- 18.1.12.2 Products/solutions/services offered
- 18.1.12.3 Recent developments
- 18.1.12.3.1 Product launches & upgrades
- 18.1.12.3.2 Deals
- 18.1.13 CUREMD HEALTHCARE
- 18.1.13.1 Business overview
- 18.1.13.2 Products/solutions/services offered
- 18.1.13.3 Recent developments
- 18.1.13.3.1 Product Launches & upgrades
- 18.1.13.3.2 Deals
- 18.1.13.3.3 Other developments
- 18.1.14 SIEMENS HEALTHINEERS AG
- 18.1.14.1 Business overview
- 18.1.14.2 Products/solutions/services offered
- 18.1.14.3 Recent developments
- 18.1.14.3.1 Products launches & upgrades
- 18.1.14.3.2 Deals
- 18.1.15 EBSCO INFORMATION SERVICES
- 18.1.15.1 Business overview
- 18.1.15.2 Products/solutions/services offered
- 18.1.15.3 Recent developments
- 18.1.15.3.1 Product launches & upgrades
- 18.1.15.3.2 Deals
- 18.1.16 GE HEALTHCARE
- 18.1.16.1 Business overview
- 18.1.16.2 Products/solutions/services offered
- 18.1.16.3 Recent developments
- 18.1.16.3.1 Product launches & upgrades
- 18.1.16.3.2 Deals
- 18.1.16.3.3 Other developments
- 18.1.17 ECLINICALWORKS, LLC
- 18.1.17.1 Business overview
- 18.1.17.2 Products/Solutions/Services Offered
- 18.1.17.3 Recent developments
- 18.1.17.3.1 Product launches & upgrades
- 18.1.17.4 Recent developments
- 18.1.17.4.1 Deals
- 18.1.18 THE MEDICAL ALGORITHMS COMPANY LIMITED
- 18.1.18.1 Business overview
- 18.1.18.2 Products/solutions/services offered
- 18.1.19 CARECLOUD, INC.
- 18.1.19.1 Business overview
- 18.1.19.2 Products/solutions/services offered
- 18.1.19.3 Recent developments
- 18.1.19.3.1 Product launches & upgrades
- 18.1.19.3.2 Deals
- 18.1.20 VISUALDX
- 18.1.20.1 Business overview
- 18.1.20.2 Products/solutions/services offered
- 18.1.20.3 Recent developments
- 18.1.20.3.1 Deals
- 18.1.1 WOLTERS KLUWER N.V.
- 18.2 OTHER PLAYERS
- 18.2.1 MACUSOFT
- 18.2.2 HERA-MI
- 18.2.3 COHESIC INC.
- 18.2.4 MEDEA MIND
- 18.2.5 GLASS HEALTH
- 18.2.6 MEDECIPHER
19 RESEARCH METHODOLOGY
- 19.1 RESEARCH APPROACH
- 19.1.1 SECONDARY RESEARCH
- 19.1.1.1 Key data from secondary sources
- 19.1.2 PRIMARY RESEARCH
- 19.1.2.1 Key data from primary sources
- 19.1.2.2 Insights from primary experts
- 19.1.1 SECONDARY RESEARCH
- 19.2 RESEARCH METHODOLOGY
- 19.3 MARKET SIZE ESTIMATION
- 19.4 MARKET BREAKDOWN DATA TRIANGULATION
- 19.5 MARKET SHARE ESTIMATION
- 19.6 STUDY ASSUMPTIONS
- 19.7 LIMITATIONS
- 19.7.1 SCOPE-RELATED LIMITATIONS
- 19.7.2 METHODOLOGY-RELATED LIMITATIONS
- 19.8 RISK ASSESSMENT
20 APPENDIX
- 20.1 DISCUSSION GUIDE
- 20.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 20.3 CUSTOMIZATION OPTIONS
- 20.4 RELATED REPORTS
- 20.5 AUTHOR DETAILS
